Harpoon Therapeutics Inc
F:5HT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Harpoon Therapeutics Inc
F:5HT
|
US |
|
Inti Bangun Sejahtera Tbk PT
IDX:IBST
|
ID |
|
C
|
China Reinsurance Group Corp
HKEX:1508
|
CN |
|
F
|
Fulongma Group Co Ltd
SSE:603686
|
CN |
|
Nuvo Pharmaceuticals Inc
TSX:MRV
|
CA |
|
MSM International Ltd
SGX:5QR
|
MY |
|
T
|
Tropicana Corporation Bhd
KLSE:TROP
|
MY |
|
Titomic Ltd
ASX:TTT
|
AU |
|
C
|
Card Factory PLC
OTC:CRFCF
|
UK |
|
S
|
Spark New Zealand Ltd
ASX:SPK
|
NZ |
Harpoon Therapeutics Inc
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. The company is headquartered in South San Francisco, California and currently employs 99 full-time employees. The company went IPO on 2019-02-08. The firm is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The company is developing a pipeline of T cell engagers using its TriTACs, focused on the treatment of solid tumors and hematologic malignancies. The company has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN328, HPN217 and HPN536. The Company’s ProTriTAC product candidate include HPN601. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells.
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. The company is headquartered in South San Francisco, California and currently employs 99 full-time employees. The company went IPO on 2019-02-08. The firm is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The company is developing a pipeline of T cell engagers using its TriTACs, focused on the treatment of solid tumors and hematologic malignancies. The company has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN328, HPN217 and HPN536. The Company’s ProTriTAC product candidate include HPN601. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
